Jade Biosciences (NASDAQ: JBIO) net income
Jade Biosciences reported a net loss of $127.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $69.6m. Earnings per share were −$3.19.
Jade Biosciences's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$127.4m | — | — | −$3.19 |
| 2024 | −$69.6m | — | — | −$2.44 |
| 2023 | −$75.5m | — | — | −$2.87 |
| 2022 | −$51.5m | — | — | −$2.10 |
| 2021 | −$23.0m | — | — | −$1.87 |
| 2020 | −$9.6m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Jade Biosciences net income compared with its sector
By net income for its latest fiscal year, Jade Biosciences ranks 361st of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 359th | Tonix Pharmaceuticals | −$124.0m | −946.2% |
| 360th | Erasca | −$124.5m | — |
| 361st | Jade Biosciences | −$127.4m | — |
| 362nd | ORIC Pharmaceuticals | −$129.5m | — |
| 363rd | Protagonist Therapeutics | −$130.1m | −282.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Jade Biosciences
- How much did Jade Biosciences earn in fiscal 2025?
- Jade Biosciences reported a net loss of $127.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $69.6m.
- What are the earnings per share of Jade Biosciences?
- They were −$3.19 in fiscal 2025, compared with −$2.44 in fiscal 2024.
- Where does Jade Biosciences rank in its sector by net income?
- It ranks 361st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Jade Biosciences come from?
- From the annual report (Form 10-K) that Jade Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Jade Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Jade Biosciences: the Jade Biosciences page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.